ea0063p518 | Calcium and Bone 2 | ECE2019
Rogers Emily
, Sagar Rebecca
, Wong Jo Ann
, Cooke Heather
, Orme Steve
, Abbas Afroze
Background: Denosumab, given 6 monthly as a subcutaneous injection, is well established as a treatment for osteoporosis. In the UK it is initiated in secondary care with most patients continuing with injections in primary care. Given concerns with hypocalcaemia and possible adverse effects on fracture risk due to abrupt cessation, robust monitoring in primary care is important. Our study compares two groups of patients on denosumab, one following a well-defined treatment pathw...